R&D Closed & Collaborative H2 2025: Mergers, acquisitions, partn... The second half of 2025 showed pharma and healthcare leaning into partnerships that de‑risk innovation and compress time to market.
News Gilead strikes deal to expand HIV drug access in 120 countri... Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free
Market Access SteinCares and Sandoz: Bringing high-quality healthcare prod... Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agree
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.